Darexaban for the prevention of venous thromboembolism in asian patients undergoing orthopedic surgery: Results from 2 randomized, placebo-controlled, double-blind studies

Clinical and Applied Thrombosis/Hemostasis

Volumn 20, Issue 2, 2014, Pages 199-211

  Fuji, Takeshi ^a   Nakamura, Mashio ^b   Takeuchi, Masahiro ^c  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^b MIE UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

deep venous thrombosis; factor Xa inhibitors; pulmonary thromboembolism; thrombosis prophylaxis; total joint arthroplasty; venous thromboembolism

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE ISOENZYME 2; DAREXABAN; ENOXAPARIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO;

ADULT; ANEMIA; ARTICLE; ASIAN; BLEEDING; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INSOMNIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MYALGIA; ORTHOPEDIC SURGERY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS HEMORRHAGE; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

DEEP VENOUS THROMBOSIS; FACTOR XA INHIBITORS; PULMONARY THROMBOEMBOLISM; THROMBOSIS PROPHYLAXIS; TOTAL JOINT ARTHROPLASTY; VENOUS THROMBOEMBOLISM;

ADULT; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ASIAN CONTINENTAL ANCESTRY GROUP; AZEPINES; BENZAMIDES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HUMANS; MALE; ORTHOPEDIC PROCEDURES; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84893473811     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612457810     Document Type: Article

References (25)

1. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007 ; 45 (2). 335-341
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 ; 133 (6 suppl). 381S - 453S
3. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients undergoing surgery. NICE Clinical Guideline 2007. http://guidance.nice.org.uk/CG92. 2007. Accessed October 10, 2011.
4. Cohen AT. Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thromb Haemost. 2010 ; 104 (5). 919-930
5. Tokyo, Japan: Nankodo ; 2008:
6. Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs. 2006 ; 66 (11). 1411-1429
7. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010 ; 70 (16). 2153-2170
8. Lee YK, Player MR. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Med Res Rev. 2011 ; 31 (2). 202-283
9. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002 ; 162 (16). 1833-1840
10. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 ; 373 (9676). 1673-1680
11. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 ; 375 (9717). 807-815
12. Eriksson BI, Turpie AG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost. 2007 ; 5 (8). 1660-1665
13. Eriksson BI, Turpie AG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost. 2010 ; 8 (4). 714-721
14. Eriksson BI, Turpie AGG, Gallus AS, et al. ONYX-3, a double-blind comparison of once- or twice-daily dosing with darexaban (YM150) (30 or 60 mg daily) for preventing venous thromboembolism after elective hip arthroplasty. J Thromb Haemost. 2011 ; 9: 855
15. Fuji T, Ochi T, Niwa S, Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci. 2008 ; 13 (5). 442-451
16. Fuji T, Fujita S, Tachibana S, et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010 ; 8 (11). 2458-2468
17. Nakamura M. Japanese Guidelines for prevention of venous thromboembolism. J Jpn Soc Clin Anesth. 2004 ; 24: 480-487
18. Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005 ; 3 (11). 2479-2486
19. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 ; 370 (9591). 949-956
20. Kobayashi T, Nakamura M, Sakuma M, et al. Incidence of pulmonary thromboembolism (PTE) and new guidelines for PTE prophylaxis in Japan. Clin Hemorheol Microcirc. 2006 ; 35 (1-2). 257-259
21. Francis CW. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2008 ;: 259-265
22. Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol. 2000 ; 85 (5). 568-572
23. Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA. Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008 ; 24 (1). 87-97
24. Frykman V, Beerman B, Ryden L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J. 2001 ; 22 (20). 1954-1959
25. Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009 ; 54 (14). 1280-1289